ES2038095T1 - Un procedimiento para la manufactura del factor de von willebrand con una pureza muy elevada. - Google Patents

Un procedimiento para la manufactura del factor de von willebrand con una pureza muy elevada.

Info

Publication number
ES2038095T1
ES2038095T1 ES199191402124T ES91402124T ES2038095T1 ES 2038095 T1 ES2038095 T1 ES 2038095T1 ES 199191402124 T ES199191402124 T ES 199191402124T ES 91402124 T ES91402124 T ES 91402124T ES 2038095 T1 ES2038095 T1 ES 2038095T1
Authority
ES
Spain
Prior art keywords
von willebrand
willebrand factor
factor
high purity
procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES199191402124T
Other languages
English (en)
Other versions
ES2038095T3 (es
Inventor
Bernard Dazey
Mohamed Hamsany
Gerard Vezon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ASSOCIATION D'AQUITAINE POUR LE DEVELOPPEMENT de la TRANSFUSION SANGUINE ET DES RECHERCHES HEMATOLOG
Original Assignee
ASSOCIATION D'AQUITAINE POUR LE DEVELOPPEMENT de la TRANSFUSION SANGUINE ET DES RECHERCHES HEMATOLOG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9399373&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2038095(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ASSOCIATION D'AQUITAINE POUR LE DEVELOPPEMENT de la TRANSFUSION SANGUINE ET DES RECHERCHES HEMATOLOG filed Critical ASSOCIATION D'AQUITAINE POUR LE DEVELOPPEMENT de la TRANSFUSION SANGUINE ET DES RECHERCHES HEMATOLOG
Publication of ES2038095T1 publication Critical patent/ES2038095T1/es
Application granted granted Critical
Publication of ES2038095T3 publication Critical patent/ES2038095T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

ESTA INVENCION SE REFIERE A UN PROCESO PARA FABRICAR EL FACTOR VON WILLEBRAND. ESTE PROCESO COMPRENDE LA ABSORCION SELECTIVA DEL FACTOR VIIIC EN EL GEL DE UNA PRIMERA COLUMNA DE CROMATOGRAFIA DE INTERCAMBIO DE IONES, ESTANDO CONTENIDO EL FACTOR VON WILLEBRAND EN LA FRACCION NO RETENIDA, Y SE CARACTERIZA EN QUE LA FRACCION NO RETENIDA SE TRATA DE TAL MANERA QUE ABSORBE EL FACTOR VON WILLEBRAND SELECTIVAMENTE EN EL GEL DE UNA SEGUNDA COLUMNA DE CROMATOGRAFIA, SIENDO OBTENIDO ENTONCES EL FACTOR Y EXPULSADO CON UNA GRAN PUREZA. LA INVENCION PERMITE OBTENER UN FACTOR VON WILLEBRAND DE UNA GRAN PUREZA, GRANDEMENTE DESPROVISTO DEL FACTOR ANTIHEMOFILICO VIIIC Y DE INACTIVADORES TALES COMO TWEEN Y TNBP, ASI COMO DE LOS PRINCIPALES CONTAMINANTES DE PLASMA.
ES91402124T 1990-08-02 1991-07-30 Procedimiento para fabricar factor von willebrand con un grado de pureza muy alto. Expired - Lifetime ES2038095T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9009917A FR2665449B1 (fr) 1990-08-02 1990-08-02 Procede de fabrication de facteur von willebrand ayant une tres haute purete, depourvu en majeure partie de facteur antihemophilique (fviiic), et facteur von willebrand ainsi obtenu, ainsi qu'une composition pharmaceutique le contenant.

Publications (2)

Publication Number Publication Date
ES2038095T1 true ES2038095T1 (es) 1993-07-16
ES2038095T3 ES2038095T3 (es) 1997-09-16

Family

ID=9399373

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91402124T Expired - Lifetime ES2038095T3 (es) 1990-08-02 1991-07-30 Procedimiento para fabricar factor von willebrand con un grado de pureza muy alto.

Country Status (9)

Country Link
US (1) US5252710A (es)
EP (1) EP0469985B1 (es)
JP (1) JP2559645B2 (es)
AT (1) ATE152128T1 (es)
DE (2) DE69125764T2 (es)
DK (1) DK0469985T3 (es)
ES (1) ES2038095T3 (es)
FR (1) FR2665449B1 (es)
GR (1) GR3024115T3 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5760183A (en) * 1989-02-17 1998-06-02 Association D'aquitaine Pour De Developpment De La Transfusion Sanguine Et Des Recherches Hematologiques Process for the manufacture of very high-purity antithaemophilic factor (FVIIIC), and von Willebrand factor, and pharmaceutical compositions containing same
US5629287A (en) * 1991-01-18 1997-05-13 University College London Depot formulations
US5610148A (en) * 1991-01-18 1997-03-11 University College London Macroscopically oriented cell adhesion protein for wound treatment
DE4435392B4 (de) * 1994-10-04 2008-02-07 Immuno Ag Verfahren zur Trennung von vWF in hochmolekularen vWF und niedermolekularen vWF
DE4435485C1 (de) * 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
US5659017A (en) * 1995-11-07 1997-08-19 Alpha Therapeutic Corporation Anion exchange process for the purification of Factor VIII
US6005077A (en) * 1995-11-10 1999-12-21 Immuno Aktiengesellschaft Use of von willebrand factor and pharmaceutical formulation
KR970060724A (ko) * 1996-01-16 1997-08-12 김광호 백업용 배터리 동작의 표시방법 및 그 감지회로
AT406867B (de) 1997-02-27 2000-10-25 Immuno Ag Verfahren zur gewinnung von hochreinem vwf oder faktor viii/vwf-komplex
AT405403B (de) 1997-02-27 1999-08-25 Immuno Ag Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie
US6531577B1 (en) * 1997-12-15 2003-03-11 Hemasure Denmark A/S von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations
EP1820516B1 (en) * 1999-02-22 2013-07-24 University of Connecticut Novel albumin-free factor VIII formulations
JP4663837B2 (ja) * 1999-12-24 2011-04-06 一般財団法人化学及血清療法研究所 第▲ｖｉｉｉ▼因子を主成分とする血小板減少に伴う出血疾患の予防・治療用医薬組成物
DE60042171D1 (de) * 1999-12-24 2009-06-18 Chemo Sero Therapeut Res Inst Faktor viii oder von willebrand faktor zur behandlung von thrombopathie assoziierenden hämorrhagischen erkrankungen
PL1656410T3 (pl) * 2003-07-22 2010-08-31 Nektar Therapeutics Sposób wytwarzania sfunkcjonalizowanych polimerów z polimerycznych alkoholi
FR2874216B1 (fr) * 2004-08-16 2006-11-03 Lab Francais Du Fractionnement Procede de preparation d'un concentre de facteur von willebrand (fvw) par voie chromatographique et concentre de fvw susceptible d'etre ainsi obtenu
WO2007011802A1 (en) 2005-07-18 2007-01-25 Nektar Therapeutics Al, Corporation Method for preparing branched functionalized polymers using branched polyol cores
KR20110017420A (ko) * 2008-06-04 2011-02-21 바이엘 헬스케어 엘엘씨 폰 빌레브란트 질환의 치료를 위한 ｆｖｉｉｉ 뮤테인
CA2742328C (en) 2008-11-07 2019-02-26 Baxter International Inc. Factor viii formulations
IT1396528B1 (it) 2009-01-19 2012-12-14 Kedrion Spa Nuovo processo di purificazione altamente selettivo di due proteine plasmatiche: von willebrand factor (vwf) e fibronectina (fn).

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4170590A (en) * 1974-12-14 1979-10-09 Biotest-Serum-Institut Gmbh Ion exchanger treatment of citrate-stabilized plasma
US4508709A (en) * 1983-12-05 1985-04-02 Armour Pharmaceutical Company Process for purifying factor VIII:C
FR2570276B1 (fr) * 1984-09-18 1987-09-04 Immunotech Sa Procede d'obtention du complexe fviii/vwf a usage therapeutique et produits en resultant
JPS63108000A (ja) * 1986-05-15 1988-05-12 Green Cross Corp:The 第８因子の精製方法
US4774323A (en) * 1987-06-29 1988-09-27 Rorer Pharmaceutical Corporation Purification of von Willebrand Factor solutions using gel permeation chromatography
NL8701915A (nl) * 1987-08-14 1989-03-01 Waander Riethorst Adsorbensmateriaal en toepassing daarvan voor het isoleren van stollingsfaktoren.
FR2632309B1 (fr) * 1988-06-07 1990-08-24 Lille Transfusion Sanguine Procede de purification par voie chromatographique de proteines, notamment de facteur viii, et les produits obtenus
FR2644064B1 (fr) * 1989-02-17 1994-05-27 Aquitaine Dev Transf Sanguine Procede de fabrication du facteur antihemophilique fviiic ayant une tres haute purete et facteur antihemophilique fviiic ainsi obtenu, ainsi que composition pharmaceutique le contenant
FR2650393A1 (fr) * 1989-07-28 1991-02-01 Herault Ctre Rgl Transfusion S Methode de purification du facteur vii (f viii) par chromatographie echangeuse d'ions

Also Published As

Publication number Publication date
DE69125764T2 (de) 1997-11-13
JPH04234400A (ja) 1992-08-24
US5252710A (en) 1993-10-12
EP0469985B1 (en) 1997-04-23
DK0469985T3 (da) 1997-10-20
EP0469985A1 (en) 1992-02-05
GR3024115T3 (en) 1997-10-31
ATE152128T1 (de) 1997-05-15
ES2038095T3 (es) 1997-09-16
DE469985T1 (de) 1992-10-15
JP2559645B2 (ja) 1996-12-04
FR2665449B1 (fr) 1995-04-14
DE69125764D1 (de) 1997-05-28
FR2665449A1 (fr) 1992-02-07

Similar Documents

Publication Publication Date Title
ES2038095T1 (es) Un procedimiento para la manufactura del factor de von willebrand con una pureza muy elevada.
IT1255983B (it) Procedimento per la purificazione di un amminoacido usando una resina scambiatrice di ioni
PL286746A1 (en) Method of obtaining a complex of antihaemophilic globulin with the willebrand factor from whole blood plasma, in the form of concentrate
ATE128950T1 (de) Verfahren zur reinigung von wasserstoffperoxyd für die mikroelektronik.
MX7552E (es) Proceso para la purificacion del factor viii c
CA2136235A1 (en) Method for purification of acetonitrile
ES2058538T3 (es) Compuestos de proteina a purificados y procedimiento para su preparacion.
DK0646594T3 (da) Fremgangsmåde til rensning af proteiner
HU9301038D0 (en) Method for producing virus-safe vii factor of high purity
ES2042027T3 (es) Procedimiento de recuperacion de acido citrico a partir de un licor que lo contiene.
DE69406803T2 (de) Adsorptionsseparationsprozess mit mehrstufigem spülen
MX9709893A (es) Fragmentos terapeuticos del factor von willebrand.
SE8201853L (sv) Flerstegs adsorptionsforfarande for separering av organiska vetskor ur vatten
FI903366A0 (fi) Foerfarande foer framstaellning av en mycket ren icke infektioes antihemofilifaktor genom kromatografi.
ES2055875T3 (es) Procedimiento de fabricacion del factor antihemofilico (fviiic) con una pureza muy elevada.
ES2049701T1 (es) Procedimiento de fabricacion de fibrinogeno con una pureza muy elevada.
ES2093780T3 (es) Procedimiento para la produccion de bisfenol a.
ES2040684T3 (es) Metodo para la regeneracion de un adsorbente de tanino.
NO832331L (no) Fremgangsmaate for rensing av soetningsmiddelopploesninger
CA2154231A1 (fr) Procede de preparation d'un concentre d'inhibiteur de la c1-esterase (c1-inh), et concentre obtenu, a usage therapeutique
KR940013535A (ko) 순수한 인 혈액 응고 제2인자 및 제9인자의 정제 방법
JPS6486871A (en) Method for separating and purifying recombinant protein

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 469985

Country of ref document: ES